{"id":"W4221036987","doi":"10.1007/s12325-022-02097-2","title":"P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease","year":2022,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Atuka (Canada); Toronto Western Hospital","funders":"Parkinsonfonden; Ipsen; H. Lundbeck A/S; Sage Therapeutics; Acorda Therapeutics; Sunovion; European Commission; Sanofi; University of South Florida; Israel Science Foundation; University of Cambridge; Boston Scientific Corporation; International Parkinson and Movement Disorder Society; Biogen; University of Oxford; Adamas Pharmaceuticals; Jazz Pharmaceuticals; National Parkinson Foundation; Teva Pharmaceutical Industries; AstraZeneca","keywords":"Rasagiline; Pramipexole; Tolerability; Levodopa; Medicine; Parkinson's disease; Selegiline; Pharmacology; Dopamine; Internal medicine; Adverse effect; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003638923,0.0004698045,0.0004361687,0.0005817633,0.0001548284,0.0006251512,0.0004141596,0.0007181557,0.002322499],"category_scores_gemma":[0.00029584,0.000157603,0.0004161221,0.0002563166,0.0002397998,0.0007277279,0.0003384912,0.001794531,0.00126161],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002335955,"about_ca_system_score_gemma":0.0003686606,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003050615,"about_ca_topic_score_gemma":0.001003726,"domain_scores_codex":[0.9998833,0.00001658532,0.00001092655,0.00002119662,0.00005278152,0.00001515908],"domain_scores_gemma":[0.9998944,0.00002664268,0.00003239847,0.000001841922,0.00001841369,0.00002635123],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004258199,0.0002143597,0.0004093825,0.003987535,0.00008083268,0.001099758,0.0001230935,0.0005615737,0.03444926,0.003745644,0.02017526,0.9347275],"study_design_scores_gemma":[0.0004740952,0.005103921,0.00369672,0.001347712,0.0002342791,0.009981819,0.00008702927,0.001013866,0.01439694,0.002375961,0.9612157,0.00007188132],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01708412,0.9613444,0.004589537,0.003118163,0.0007619868,0.0001041815,0.0002677559,0.0002350584,0.01249491],"genre_scores_gemma":[0.05867412,0.9224629,0.005839105,0.002698026,0.0007693632,0.00010757,0.0005341438,0.00002995403,0.008884907],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002322499,"threshold_uncertainty_score":0.007769525,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06135916018494184,"score_gpt":0.3735306502470583,"score_spread":0.3121714900621164,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}